Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of subcutaneous JKN2401 in adults with inadequately controlled severe asthma
CTR20261006Phase 2Active
- Sponsor
- Quxin Biopharmaceutical
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JKN2401 in asthma, severe asthma, sponsored by Quxin Biopharmaceutical. Started Mar 2026; status: active.
02
Drugs
JKN2401
03
Conditions
asthmasevere asthma
Beyond the preview
Go deeper on CTR20261006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261006.